Literature DB >> 10569164

Cystoid macular edema after phacoemulsification: relationship to blood-aqueous barrier damage and visual acuity.

P G Ursell1, D J Spalton, S M Whitcup, R B Nussenblatt.   

Abstract

PURPOSE: To ascertain the incidence of cystoid macular edema (CME) after phacoemulsification and its relationship to blood-aqueous barrier damage and visual acuity.
SETTING: A British teaching hospital.
METHODS: A prospective trial was performed to document the incidence of CME after routine phacoemulsification with continuous curvilinear capsulorhexis. LogMAR visual acuity and laser flare were measured using the KOWA FC 1000 laser cell-flare meter preoperatively and 1, 14, 30, and 60 days postoperatively. At day 60, a standardized fluorescein angiogram was performed and graded by masked observers.
RESULTS: The rate of angiographic CME on day 60 was 19%. Visual acuity at each visit was significantly worse in the CME group (P < .05). The flare and cell values at days 14, 30, and 60 were higher in the CME group at day 60; however, the difference was not statistically significance (P > .05).
CONCLUSIONS: The incidence of CME after routine phacoemulsification was 19%. Patients with CME at day 60 had significantly worse visual acuity than those who did not from the first postoperative day throughout the follow-up. There was a trend for patients who had CME at day 60 to have more postoperative inflammation.

Entities:  

Mesh:

Year:  1999        PMID: 10569164     DOI: 10.1016/s0886-3350(99)00196-0

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  49 in total

Review 1.  Is it time for a new attitude to "simultaneous" bilateral cataract surgery?

Authors:  G T Smith; C S Liu
Journal:  Br J Ophthalmol       Date:  2001-12       Impact factor: 4.638

2.  Cystoid macular oedema with trypan blue use.

Authors:  P Gouws; M Merriman; S Goethals; P R Simcock; R J Greenwood; G Wright
Journal:  Br J Ophthalmol       Date:  2004-10       Impact factor: 4.638

3.  Cystoid macular oedema with trypan blue use.

Authors:  H K L Yuen; R F Lam; D S C Lam
Journal:  Br J Ophthalmol       Date:  2005-05       Impact factor: 4.638

4.  Outcome of phacoemulsification in patients with uveitis.

Authors:  M A Elgohary; P J McCluskey; H M A Towler; N Okhravi; R P Singh; R Obikpo; S S Lightman
Journal:  Br J Ophthalmol       Date:  2007-01-17       Impact factor: 4.638

5.  Macular thickness after uneventful cataract surgery determined by optical coherence tomography.

Authors:  Burkhard von Jagow; Christian Ohrloff; Thomas Kohnen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-07-10       Impact factor: 3.117

6.  Assessing the effects of ketorolac and acetazolamide on macular thickness by optical coherence tomography following cataract surgery.

Authors:  Ece Turan-Vural; Elvin Halili; Didem Serin
Journal:  Int Ophthalmol       Date:  2014-06       Impact factor: 2.031

7.  Which procedure has more effect on macular thickness: primary posterior continuous capsulorhexis (PPCC) combined with phacoemulsification or Nd:YAG laser capsulotomy?

Authors:  Necip Kara; Ahmet Taylan Yazici; Ercument Bozkurt; Yusuf Yildirim; Ahmet Demirok; Omer Faruk Yilmaz
Journal:  Int Ophthalmol       Date:  2011-08-14       Impact factor: 2.031

8.  Intravitreal Dexamethasone Implantation in Intravitreal Bevacizumab Treatment-resistant Pseudophakic Cystoid Macular Edema.

Authors:  Ayse Gul Kocak Altintas; Cagri Ilhan
Journal:  Korean J Ophthalmol       Date:  2019-06

Review 9.  Cataract surgery and nonsteroidal antiinflammatory drugs.

Authors:  Richard S Hoffman; Rosa Braga-Mele; Kendall Donaldson; Geoffrey Emerick; Bonnie Henderson; Malik Kahook; Nick Mamalis; Kevin M Miller; Tony Realini; Neal H Shorstein; Richard K Stiverson; Barbara Wirostko
Journal:  J Cataract Refract Surg       Date:  2016-09       Impact factor: 3.351

10.  Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%.

Authors:  Seenu M Hariprasad; Levent Akduman; Joseph A Clever; Michael Ober; Franco M Recchia; William F Mieler
Journal:  Clin Ophthalmol       Date:  2009-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.